28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
The county clusters with the highest and lowest AD mortality rates were in Washington (WA) and New York (NY), respectively, with other notable high-mortality clusters on the border of Tennessee, Georgia, and Alabama as well as in North Dakota and South Dakota. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In China, the crude mortality from AD and other forms of dementia increased from 2009 to 2015, but the age-standardized mortality decreased. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
; 95% CI: 1.01, 1.04). Neighborhood environment features, such as higher air pollution levels, were associated with higher neighborhood ADRD incidence. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The nationwide combined weighted PAF for the eight CMDs was 37% overall, with hypertension (9.6%), ischemic heart disease (6.7%), and chronic heart failure (5.7%) associated with the greatest attributable fractions of dementia cases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Place-based SDoH measures were higher in Black compared to White participants. 3 key findings →
Participants: 679 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We found a dose‐dependent association between ADI and dementia The ADI may be a valuable tool for identifying high‐risk communities for dementia intervention. 5 key findings →
Participants: 1,395,872 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Participants' age ranged from 45 to 87, 53% were women, and 26% were diagnosed with dementia (39% AD, 18% Lewy Body and 17% Frontotemporal Dementia; Table 1). 5 key findings →
Design: cross-sectional Participants: 255 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This study reveals significant differences in driving patterns between cognitively normal older adults and those with cognitive impairment. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Ten‐year Black‐White disparities in prison population are associated with cognitive decline among people racialized as Black starting one year later. 5 key findings →
Participants: 2,300 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Central-northern rural communities exhibited the most pronounced high-high spatial clustering of cognitive impairment (Global Moran's I = 0.17, p < 0.001). 5 key findings →
Design: cross-sectional Participants: 18,963 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Overall, 64% of PlwAD received at least one AD-Rx. 5 key findings →
Participants: 576 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A total of 260,200 older adults were screened for delirium (median [IQR] age in years: 78.0 [74.0-84.0]; female: 143,402 [55.1%]; non-Hispanic Black: 40,737 [15.8%]; Hispanic: 30,760 [11.9%]; median [IQR] Area Deprivation Index: 4.0 [2.0-6.0]; median [IQR] Charlson Comorbidity Index: 10.0 [8.0-13.0]). 5 key findings →
Participants: 260,200 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
It is imperative to recognize and mitigate persistent disparities in the COVID‐19 pandemic, particularly pertaining to participation in long‐COVID research. 5 key findings →
Participants: 1,046 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Participants with impaired hearing (n = 179) were older (73.9 vs. 71.4 years, p <0.001), often male (61.5% vs. 36.5%, p <0.001), and had lower cognitive scores than normal-hearing individuals (n = 241). 5 key findings →
Design: cross-sectional Participants: 179 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Living in more deprived neighborhoods was associated with an accelerated disease course in bvFTD, highlighting an important socioeconomic disparity in disease prognosis. 3 key findings →
Design: longitudinal study Participants: 161 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Plasma biomarkers showed promising diagnostic performances and potential clinical usefulness in diagnosing dementia. 2 key findings →
Participants: 51 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
and amyloid composite in the context of AD. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The approval of disease-modifying antiamyloid therapies has expanded the clinical role of amyloid PET beyond diagnostic confirmation to include baseline characterization and longitudinal monitoring of treatment response. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Systemic inflammatory biomarkers were primarily associated with age/socio-demographic characteristics, remained strikingly stable over time, and were not associated with AD progression. 5 key findings →
Participants: 333 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
= 0.032). In individuals with LOUE, elevated plasma p-tau217 was associated with both cognitive impairment and disrupted sleep microarchitecture, with the most pronounced cognitive deficits observed in individuals with medication refractory epilepsy. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dream recall status was associated with blood p ‐tau217 levels, APOE ε4 carriage, and future cognitive decline among older individuals cognitively healthy at baseline. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Non-core NfL and GFAP biomarkers are associated with both cross-sectional and longitudinal cognitive performance. 5 key findings →
Design: cross-sectional Participants: 334 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
BackgroundSystemic inflammation has been implicated in cognitive aging and neurodegeneration; however, inflammatory biomarkers are expressed in coordinated patterns rather than as isolated markers. 4 key findings →
Design: cross-sectional Participants: 334 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Although apolipoprotein E (ApoE) ε4 is a well-established risk factor for Alzheimer disease, its role in the development of post-stroke cognitive impairment (PSCI) remains uncertain. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among most Latinos in northern Manhattan who learned they had an APOE ε4/ε4 genotype, disclosure did not provoke elevated levels of distress. 3 key findings →
Participants: 61 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →